Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hyman

Showing results (321-330 of 401) with videos related to

Pageof 41
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2014
Opinion: Mathematical models: a key tool for outbreak responseEric T Lofgren, M Elizabeth Halloran, Caitlin M Rivers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant CancersKomal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Nature Communications|April 20, 2022
AKT mutant allele-specific activation dictates pharmacologic sensitivitiesTripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, et al.
JCO Precision Oncology|April 7, 2018
Successful Targeted Therapy of Refractory Pediatric <i>ETV6-NTRK3</i> Fusion-Positive Secretory Breast CarcinomaNeerav Shukla, Stephen S Roberts, Mollah O Baki, et al.
JCO Precision Oncology|July 12, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket StudyLillian M Smyth, Jonathan B Reichel, Jiabin Tang, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Cancer Discovery|October 18, 2014
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disordersDavid M Hyman, Eli L Diamond, Cecile Rose T Vibat, et al.
Pageof 41

Showing results (321-330 of 401) with videos related to

Sort By:
Pageof 41
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2014
Opinion: Mathematical models: a key tool for outbreak responseEric T Lofgren, M Elizabeth Halloran, Caitlin M Rivers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant CancersKomal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Nature Communications|April 20, 2022
AKT mutant allele-specific activation dictates pharmacologic sensitivitiesTripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, et al.
JCO Precision Oncology|April 7, 2018
Successful Targeted Therapy of Refractory Pediatric <i>ETV6-NTRK3</i> Fusion-Positive Secretory Breast CarcinomaNeerav Shukla, Stephen S Roberts, Mollah O Baki, et al.
JCO Precision Oncology|July 12, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket StudyLillian M Smyth, Jonathan B Reichel, Jiabin Tang, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Cancer Discovery|October 18, 2014
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disordersDavid M Hyman, Eli L Diamond, Cecile Rose T Vibat, et al.
Pageof 41